NCT00349141View on ClinicalTrials.gov

Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

270

Participants

Timeline

Start Date

June 30, 2006

Conditions

Influenza

Interventions

BIOLOGICAL

Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen

Trial Locations (3)

1090

University Hospital, Department of Clinical Pharmacology, General Hospital Vienna, Vienna

119074

National University Hospital, Singapore

529889

Changi General Hospital, Singapore

All Listed Sponsors

lead

Alachua Government Services, Inc.

INDUSTRY

NCT00349141 - Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) | Biotech Hunter | Biotech Hunter